Carregant...
SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
BACKGROUND: Cisplatin (DDP) remains the backbone of chemotherapy for non-small cell lung cancer (NSCLC), yet its clinical efficacy is limited by DDP resistance. We aim to investigate the role of the SET and MYND domain-containing protein 3 (SMYD3) in DDP resistance of NSCLC. METHODS: Expression patt...
Guardat en:
| Publicat a: | Transl Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Neoplasia Press
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8027902/ https://ncbi.nlm.nih.gov/pubmed/33773404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101075 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|